ANX Mast Therapeutics, Inc.

SAN DIEGO, April 6 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) today announced that Brian M. Culley, vice president of business development, is scheduled to present at the BIO 2006 Conference Business Forum on Monday, April 10th at 5:00 p.m. CDT in Room C, McCormick Place South, Level 3 Exhibit Hall A. The annual conference is sponsored by the Biotechnology Industry Organization (BIO) and takes place April 9-12, 2006 at the McCormick Place Convention Center in Chicago, IL. For more information on this conference visit http://www.bio.org/. About ADVENTRX ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on introducing new technologies for anticancer and antiviral treatments that surpass the performance and safety of existing drugs, by addressing significant problems such as drug metabolism, toxicity, bioavailability and resistance. More information can be found on the Company's Web site at http://www.adventrx.com/. Forward Looking Statement This press release contains forward-looking statements, within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, regarding ADVENTRX. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the FDA and other regulatory agencies. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements regarding ADVENTRX, see the section titled "Risk Factors" in ADVENTRX's last annual report on Form 10-K, as well as other reports that ADVENTRX files from time to time with the Securities and Exchange Commission. All forward-looking statements regarding ADVENTRX are qualified in their entirety by this cautionary statement. ADVENTRX undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof. DATASOURCE: ADVENTRX Pharmaceuticals, Inc. CONTACT: Andrea Lynn of ADVENTRX Pharmaceuticals, Inc., +1-858-552-0866 Web site: http://www.bio.org/ Web site: http://www.adventrx.com/ Company News On-Call: http://www.prnewswire.com/comp/920134.html Company News On-Call: http://www.prnewswire.com/comp/638610.html

Copyright